Lisata Therapeutics Stock Alpha and Beta Analysis
| LSTA Stock | USD 2.58 0.15 5.49% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Lisata Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Lisata Therapeutics over a specified time horizon. Remember, high Lisata Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Lisata Therapeutics' market risk premium analysis include:
Beta (0.42) | Alpha (0.16) | Risk 3.07 | Sharpe Ratio (0.05) | Expected Return (0.17) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Lisata |
Lisata Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Lisata Therapeutics market risk premium is the additional return an investor will receive from holding Lisata Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Lisata Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Lisata Therapeutics' performance over market.| α | -0.16 | β | -0.42 |
Lisata Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Lisata Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Lisata Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Lisata Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Lisata Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Lisata Therapeutics shares will generate the highest return on investment. By understating and applying Lisata Therapeutics stock market price indicators, traders can identify Lisata Therapeutics position entry and exit signals to maximize returns.
Lisata Therapeutics Return and Market Media
The median price of Lisata Therapeutics for the period between Wed, Sep 18, 2024 and Tue, Dec 17, 2024 is 2.91 with a coefficient of variation of 4.11. The daily time series for the period is distributed with a sample standard deviation of 0.12, arithmetic mean of 2.89, and mean deviation of 0.09. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Alamar Biosciences Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinsons Research Through Development of Next Generation Biomarker As... | 11/19/2024 |
2 | Neurogene and Ventyx Biosciences rises after insider buying by executives | 11/26/2024 |
3 | Vevo Therapeutics faz parceria com a Parse Biosciences GigaLab para gerar um atlas de 100 milhes de clulas para descoberta de medicamentos com tecnologia de IA | 12/05/2024 |
4 | Castle Biosciences CEO Derek Maetzold sells 160,741 in shares | 12/09/2024 |
5 | Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring | 12/10/2024 |
6 | Why Pacific Biosciences of California Is the Worst ARK Stock to Buy According to Short Sellers | 12/11/2024 |
7 | Riassunto Parse Biosciences lancia Evercode Mouse BCR per supportare la progettazione e lo sviluppo di anticorpi per applicazioni di scoperta di farmaci | 12/12/2024 |
8 | Solid Biosciences SWOT analysis gene therapy stocks potential in DMD treatment | 12/13/2024 |
About Lisata Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Lisata or other stocks. Alpha measures the amount that position in Lisata Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Payables Turnover | 0.0781 | 0.0742 | Days Of Inventory On Hand | 4.4K | 4.6K |
Lisata Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Lisata Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lisata Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Lisata Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Lisata Therapeutics. Please utilize our Beneish M Score to check the likelihood of Lisata Therapeutics' management manipulating its earnings.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Lisata Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Lisata Therapeutics Backtesting, Lisata Therapeutics Valuation, Lisata Therapeutics Correlation, Lisata Therapeutics Hype Analysis, Lisata Therapeutics Volatility, Lisata Therapeutics History and analyze Lisata Therapeutics Performance. For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Lisata Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.